Drug intelligence / Profile preview

PBGENE-LLY3

Development stage: Unknown
Lead developer: Precision BioSciences
Modality: Gene Therapies
Administration: Unknown

Overview

PBGENE-LLY3 is an investigational gene editing therapy developed by Precision BioSciences for central nervous system (CNS) related disorders. It employs the ARCUS gene editing platform, which is based on proprietary meganucleases engineered to enable targeted gene modification. PBGENE-LLY3 is designed as a CNS-directed gene modulator, aiming to correct, modulate, or eliminate disease-driving genetic defects within the nervous system. As of 2025, development was discontinued at a preclinical phase. Details about the exact target gene or specific CNS disease indication have not been publicly disclosed.

Brand names: PBGENE-LLY3PBGENE-LLY-3PBGENE-LLY 3
Other names: PBGENE-LLY3PBGENE-LLY-3PBGENE-LLY 3PBGENELLY3PBGENELLY-3PBGENELLY 3

Beyond the preview

Go deeper on PBGENE-LLY3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBGENE-LLY3.

Explore the full profile